

- Public and private programs should support training for health professionals to emphasize proactive, individualized care planning and clear communication between providers, patients and their families.

- At the community level, funding should be made available for support services to assist individuals and families in accessing the kind of care they want for last days.

Members of the Citizens' Health Care Working Group

Randall L. Johnson, Chair

Frank J. Baumeister, Jr.

Dorothy A. Bazos

Montye S. Conlan

Richard G. Frank

Joseph T. Hansen

Therese A. Hughes

Brent C. James

Catherine G. McLaughlin

Patricia A. Maryland

Rosario Perez

Aaron Shirley

Deborah R. Stehr

Christine L. Wright

Michael O. Leavitt, Secretary of Health and Human Services

Because the Working Group's final recommendations will be submitted to the Department of Health and Human Services, the Secretary of Health and Human Services has neither participated in the development of these recommendations nor has he endorsed them. He will carefully consider them and take appropriate action.

#### End of Review Text

Additional materials including a description of how the Working Group did its work, key findings from the dialogue with the American people, stories from Americans, and background material on the demographics and health resources of locations where Working Group community meetings were held, findings from the Working Group's internet poll and University town hall meeting, and a summary of presentations made to the Working Group can be found on the Working Group's Web site:

[www.citizenshealthcare.gov](http://www.citizenshealthcare.gov).

**Authority:** This notice is published in accordance with section 10(a) of the Federal Advisory Committee Act.

The Medicare Modernization Act charged AHRQ with administering the funds provided by the Congress for the activities of the Citizens' Health Care Working Group. However, AHRQ has not participated in the development of these recommendations or supporting material, has had not advance knowledge of their content, and publication of this notice is not an

endorsement of the Working Group's recommendations by AHRQ or the Department of Health and Human Services.

**Carolyn M. Clancy,**

*Director.*

[FR Doc. 06-5379 Filed 6-13-06; 8:45 am]

**BILLING CODE 4160-90-M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Agency for Healthcare Research and Quality

#### Notice of Meeting

In accordance with section 10(d) of the Federal Advisory Committee Act (5 U.S.C., Appendix 2), announcement is made of a Health Care Policy and Research Special Emphasis Panel (SEP) meeting.

A Special Emphasis Panel is a group of experts in fields related to health care research who are invited by the Agency for Healthcare Research and Quality (AHRQ), and agree to be available, to conduct on an as needed basis, scientific reviews of applications for AHRQ support. Individual members of the Panel do not attend regularly-scheduled meetings and do not serve for fixed terms or a long period of time. Rather, they are asked to participate in particular review meetings which require their type of expertise.

Substantial segments of the upcoming SEP meeting listed below will be closed to the public in accordance with the Federal Advisory Committee Act, section 10(d) of 5 U.S.C., Appendix 2 and 5 U.S.C. 552b(c)(6). Grant applications submitted in response to the Request for Applications (RFA) Number: RFA-HS-06-030, Improving Patient Safety through Simulation Research, are to be reviewed and discussed at this meeting. These discussions are likely to reveal personal information concerning individuals associated with the applications. This information is exempt from mandatory disclosure under the above-cited statutes.

**SEP Meeting on:** Improving Patient Safety through Simulation Research, July 11-13, 2006.

**Date:** July 11, 2006 (Open on July 11 from 7 p.m. to 7:15 p.m. and closed for the remainder of the meeting).

**Place:** Marriott Gaithersburg Washingtonian, 9751 Washingtonian Boulevard, Gaithersburg, MD 20878.

**Date:** July 12-13, 2006 (Closed meeting).

**Place:** John M. Eisenberg Building, 540 Gaither Road, Suite 2020, Rockville, Maryland 20850.

**Contact Person:** Anyone wishing to obtain a roster of members, agenda or minutes of the non-confidential portions of this meeting should contact Mrs. Bonnie Campbell, Committee Management Officer, Office of Extramural Research, Education and Priority Populations, AHRQ, 540 Gaither Road, Room 2038, Rockville, Maryland 20850, telephone (301) 427-1554.

Agenda items for this meeting are subject to change as priorities dictate.

Dated: June 2, 2006.

**Carolyn M. Clancy,**

*Director.*

[FR Doc. 06-5378 Filed 6-13-06; 8:45 am]

**BILLING CODE 4160-90-M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### Disease, Disability, and Injury Prevention and Control Special Emphasis Panels: Prevention of the Complications of Bleeding Disorders Through Hemophilia Treatment Centers, Request for Applications (RFA) DD06-005

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the following meeting:

**Name:** Disease, Disability, and Injury Prevention and Control Special Emphasis Panel: Prevention of the Complications of Bleeding Disorders through Hemophilia Treatment Centers, RFA DD06-005.

**Time and Date:** 8 a.m.-5 p.m., June 28, 2006 (Closed).

**Place:** Centers for Disease Control and Prevention, 1600 Clifton Road, NE., Building 19, Room 256/257, Atlanta, GA 30333.

**Status:** The meeting will be closed to the public in accordance with provisions set forth in section 552b(c)(4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92-463.

**Matters To Be Discussed:** To conduct expert review of scientific merit of research applications in response to RFA DD06-005, "Prevention of the Complications of Bleeding Disorders through Hemophilia Treatment Centers."

**For Further Information Contact:**

Juliana Cyril, Ph.D., Scientific Review Administrator, Centers for Disease Control and Prevention, 1600 Clifton Road, NE., Mailstop D72, Atlanta, GA 30333, Telephone 404.639.4639.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both CDC and the Agency for Toxic Substances and Disease Registry.

Dated: June 8, 2006.

**Alvin Hall,**

*Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.*

[FR Doc. E6-9269 Filed 6-13-06; 8:45 am]

**BILLING CODE 4163-18-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### Disease, Disability, and Injury Prevention and Control Special Emphasis Panel: HIV Prevention Projects for Young Men of Color Who Have Sex With Men and Young Transgender Persons of Color, Funding Opportunity Announcement (FOA) PS06-618

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the following meeting:

*Name:* Disease, Disability, and Injury Prevention and Control Special Emphasis Panel: HIV Prevention Projects for Young Men of Color Who Have Sex With Men and Young Transgender Persons of Color, FOA PS06-618.

*Times and Dates:*

9 a.m.–12 p.m., June 26, 2006 (Closed).  
9 a.m.–5 p.m., June 27, 2006 (Closed).  
9 a.m.–5 p.m., June 28, 2006 (Closed).  
9 a.m.–5 p.m., June 29, 2006 (Closed).  
9 a.m.–5 p.m., June 30, 2006 (Closed).

*Place:* W Hotel Atlanta at Perimeter Center, 111 Perimeter Center West, Atlanta, Georgia 30346, Telephone 770.396.6800.

*Status:* The meeting will be closed to the public in accordance with provisions set forth in section 552b(c)(4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92-463.

*Matters To Be Discussed:* The meeting will include the review, discussion, and evaluation of applications received in response to "HIV Prevention Projects for Young Men of Color Who Have Sex With Men and Young Transgender Persons of Color," FOA PS06-618.

*For Further Information Contact:* Beth Wolfe, Resource Funding Analyst, Funding Activities Services Office, Extramural Funding Activities Unit, National Center for HIV, STD, and TB Prevention, Centers for Disease Control

and Prevention, 1600 Clifton Road NE., MS E-07, Atlanta, GA 30333, Telephone 404.639.8531.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both CDC and the Agency for Toxic Substances and Disease Registry.

Dated: June 8, 2006.

**Alvin Hall,**

*Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.*

[FR Doc. E6-9270 Filed 6-13-06; 8:45 am]

**BILLING CODE 4163-18-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### Advisory Committee on Immunization Practices: Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the following Federal Committee meeting.

*Correction:* This notice was published in the **Federal Register** on June 9, 2006, volume 71, number 111, pages 33456-33457. "Additional Information" that was published on April 3, 2006, volume 71, number 63, page 16582, and a change to the 'status' has been added.

*Name:* Advisory Committee on Immunization Practices (ACIP).

*Times and Dates:*

8 a.m.–6 p.m., June 29, 2006.  
8 a.m.–4 p.m., June 30, 2006.

*Place:* Centers for Disease Control and Prevention, 1600 Clifton Road, NE., Building 19 (Global Communications Center), Room 232, Atlanta, Georgia 30333.

*Status:* Open to the public, limited only by the space available. Meeting space accommodates approximately 330 people. Overflow space for real-time viewing will be available.

*Additional Information:* In order to expedite the security clearance process at the CDC Clifton Road Campus, all ACIP attendees are now required to register online at <http://www.cdc.gov/nip/acip>, which can be found under the "Upcoming Meetings" tab. Please be sure to complete all the required fields before submitting your registration and submit no later than June 22, 2006.

**Please Note:** All non-U.S. Citizens must pre-register by June 18, 2006 or they will not be allowed access to the campus and will *not* be allowed to register on site. All non-U.S. Citizens are required to complete the "Access

Request Form" and register online at <http://www.cdc.gov/nip/acip>. The access request form can be obtained by contacting Demetria Gardner at 1-404-639-8836 and should be e-mailed upon completion directly to Ms. Gardner at [dgardner@cdc.gov](mailto:dgardner@cdc.gov).

*For Further Information Contact:* Demetria Gardner, Immunization Services Division, National Center for Immunization and Respiratory Diseases (proposed), CDC, 1600 Clifton Road, NE., (E-05), Atlanta, Georgia 30333, telephone 404/639-8836, fax 404/639-8905.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities for both the CDC and the Agency for Toxic Substances and Disease Registry.

Dated: June 8, 2006.

**B. Kathy Skipper,**

*Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.*

[FR Doc. E6-9266 Filed 6-13-06; 8:45 am]

**BILLING CODE 4163-18-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. 2002E-0100]

#### Determination of Regulatory Review Period for Purposes of Patent Extension; DUTASTERIDE

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) has determined the regulatory review period for DUTASTERIDE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.

**ADDRESSES:** Submit written comments and petitions to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Submit electronic comments to <http://www.fda.gov/dockets/ecomments>.

**FOR FURTHER INFORMATION CONTACT:** Beverly Friedman, Office of Regulatory Policy (HFD-7), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-594-2041.

**SUPPLEMENTARY INFORMATION:** The Drug Price Competition and Patent Term Restoration Act of 1984 (Public Law 98-